AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9407377 — intervention group
Group type: COMPARATOR
Intervention: Zidovudine (ZDV) alone
Number of subjects: 33
Study 8428855 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline 300 mg twice a day (R1)
Number of subjects: 25
Study 8428855 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol 4 mg tid (R2)
Number of subjects: 25
Study 8428855 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (200/4mg, R3)
Number of subjects: 25
Study 8428855 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (100/2mg, R4)
Number of subjects: 25
Study 8428855 — intervention group
Group type: COMPARATOR
Intervention: Placebo (calcium lactate 300 mg) tid (R5)
Number of subjects: 25
Study 3309901 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceruletide 0.3 microgram/kg b.wt. injected IM 30 min before lunch
Number of subjects: 14
Study 3309901 — intervention group
Group type: COMPARATOR
Intervention: Placebo injected IM 30 min before lunch
Number of subjects: 14
Study 3309901 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceruletide
Number of subjects: 14
Study 31300213 — intervention group
Group type: EXPERIMENTAL
Intervention: Iodine-125 (125I) seeds
Number of subjects: 98
Study 31300213 — intervention group
Group type: COMPARATOR
Intervention: Surgical clips
Number of subjects: 98
Study 30389802 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored Feedback (TF)
Number of subjects: 1054
Study 30389802 — intervention group
Group type: COMPARATOR
Intervention: Standard Leaflet (SL)
Number of subjects: 1054
Study 30389802 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 1054
Study 27098449 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary feedback and weekly text messages
Number of subjects: 247
Study 27098449 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary feedback only
Number of subjects: 247
Study 27098449 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 247
Study 25707517 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolic acid (MPA)
Number of subjects: 70
Study 25707517 — intervention group
Group type: EXPERIMENTAL
Intervention: Population pharmacokinetic model
Number of subjects: 70
Study 23802840 — intervention group
Group type: EXPERIMENTAL
Intervention: Saxagliptin 2.5, 5 or 10 mg/day
Number of subjects: 1144
Study 23802840 — intervention group
Group type: EXPERIMENTAL
Intervention: Saxagliptin plus metformin
Number of subjects: 1144
Study 23802840 — intervention group
Group type: EXPERIMENTAL
Intervention: Saxagliptin
Number of subjects: 1144
Study 23802840 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1144
Study 21449914 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg risperidone
Number of subjects: 72
Study 19468932 — intervention group
Group type: EXPERIMENTAL
Intervention: Predispositional engagement (Need for Cognition, Mindfulness, Openness to Experience)
Number of subjects: 0
Study 19468932 — intervention group
Group type: EXPERIMENTAL
Intervention: Activity engagement
Number of subjects: 0
Study 19468932 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognition (working memory, processing speed, divergent thinking, inductive reasoning, visuo-spatial processing)
Number of subjects: 0
Study 16390852 — intervention group
Group type: EXPERIMENTAL
Intervention: Impaired renal function (estimated glomerular filtration rate <60 ml/min/1.73 m²) in men and women aged 65 years or older
Number of subjects: 6317
Study 16390852 — intervention group
Group type: COMPARATOR
Intervention: Cardiovascular risk factors (smoking, obesity, blood lipid levels, high systolic blood pressure, hyperuricaemia)
Number of subjects: 6317
Study 16390852 — intervention group
Group type: COMPARATOR
Intervention: Cardiovascular drug prescriptions (angiotensin-converting enzyme inhibitors and beta-blockers)
Number of subjects: 6317
Study 15286545 — intervention group
Group type: EXPERIMENTAL
Intervention: Early percutaneous tracheotomy within 48 hours
Number of subjects: 120
Study 15286545 — intervention group
Group type: COMPARATOR
Intervention: Delayed tracheotomy at days 14-16
Number of subjects: 120
Study 10939683 — intervention group
Group type: EXPERIMENTAL
Intervention: Scopolamine (1.5 mg, transdermal patch)
Number of subjects: 0
Study 10939683 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclizine (50 mg tablet)
Number of subjects: 0
Study 10939683 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 9293194 — intervention group
Group type: EXPERIMENTAL
Intervention: Dental history questionnaire
Number of subjects: 74
Study 9293194 — intervention group
Group type: COMPARATOR
Intervention: Slides of dental procedures
Number of subjects: 74
Study 9293194 — intervention group
Group type: COMPARATOR
Intervention: No manipulation (Control)
Number of subjects: 74
Study 8421116 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05% sodium fluoride and 0.05% chlorhexidine rinse
Number of subjects: 47
Study 8421116 — intervention group
Group type: COMPARATOR
Intervention: Placebo rinse
Number of subjects: 47
Study 2892545 — intervention group
Group type: EXPERIMENTAL
Intervention: Etintidine (400 mg)
Number of subjects: 10
Study 2892545 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 29941296 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 75
Study 29941296 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Number of subjects: 75
Study 29941296 — intervention group
Group type: COMPARATOR
Intervention: Risperidone and Aripiprazole
Number of subjects: 75
Study 27294877 — intervention group
Group type: EXPERIMENTAL
Intervention: Mandibular block anesthesia (group A; n=10)
Number of subjects: 20
Study 27294877 — intervention group
Group type: COMPARATOR
Intervention: Local infiltration anesthesia (group B; n=10)
Number of subjects: 20
Study 25000437 — intervention group
Group type: EXPERIMENTAL
Intervention: Levobupivacaine 0.5%
Number of subjects: 5
Study 25000437 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.5%
Number of subjects: 5
Study 25000437 — intervention group
Group type: COMPARATOR
Intervention: Saline (Control)
Number of subjects: 5
Study 23378456 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat strawberry kefir
Number of subjects: 10
Study 23378456 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat orange kefir
Number of subjects: 10
Study 23378456 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat plain kefir
Number of subjects: 10
Study 23378456 — intervention group
Group type: COMPARATOR
Intervention: Kefir (all types)
Number of subjects: 10
Study 23378456 — intervention group
Group type: COMPARATOR
Intervention: White bread
Number of subjects: 10
Study 19350339 — intervention group
Group type: EXPERIMENTAL
Intervention: Strontium ranelate treatment
Number of subjects: 0
Study 19350339 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 0
Study 18242076 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen
Number of subjects: 123
Study 18242076 — intervention group
Group type: EXPERIMENTAL
Intervention: TACE
Number of subjects: 123
Study 22078189 — intervention group
Group type: EXPERIMENTAL
Intervention: Mifepristone 25 mg twice daily on day 1 plus placebo 1 daily for 4 days
Number of subjects: 0
Study 22078189 — intervention group
Group type: EXPERIMENTAL
Intervention: Mifepristone 25 mg twice daily on day 1 plus ethinyl estradiol (EE) 20 mcg daily for days 2-5
Number of subjects: 0
Study 22078189 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 15643104 — intervention group
Group type: EXPERIMENTAL
Intervention: Flutamide
Number of subjects: 46
Study 15643104 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram
Number of subjects: 46
Study 15643104 — intervention group
Group type: EXPERIMENTAL
Intervention: Flutamide plus Citalopram
Number of subjects: 46
Study 15643104 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study 12243210 — intervention group
Group type: EXPERIMENTAL
Intervention: Antipsychotics
Number of subjects: 34
Study 12243210 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 11477920 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated traditional Chinese and Western medicine (TCM‐WM) therapy
Number of subjects: 30
Study 11477920 — intervention group
Group type: COMPARATOR
Intervention: Control (healthy subjects)
Number of subjects: 30
Study 11477920 — intervention group
Group type: COMPARATOR
Intervention: Western medicine (WM) alone
Number of subjects: 30
Study 8576842 — intervention group
Group type: EXPERIMENTAL
Intervention: Teicoplanin loading doses of 6 to 30 mg/kg, followed by once-a-day treatment of approximately the same doses over several weeks.
Number of subjects: 197
Study 8576842 — intervention group
Group type: EXPERIMENTAL
Intervention: FPIA assay method
Number of subjects: 197
Study 2909202 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human erythropoietin (r‐HuEPO) 50, 100, or 150 IU/kg body weight
Number of subjects: 14
Study 2909202 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human erythropoietin (r‐HuEPO)
Number of subjects: 14
Study 2909202 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 782764 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A alcohol in oil-water emulsion
Number of subjects: 43
Study 782764 — intervention group
Group type: COMPARATOR
Intervention: Vitamin A alcohol in oil
Number of subjects: 43
Study 782764 — intervention group
Group type: COMPARATOR
Intervention: Vitamin A palmitate in oil-water emulsion
Number of subjects: 43
Study 782764 — intervention group
Group type: COMPARATOR
Intervention: Vitamin A palmitate in oil
Number of subjects: 43
Study 11550727 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive‐behavioral therapy (CBT)
Number of subjects: 219
Study 11550727 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral weight control
Number of subjects: 219
Study 11550727 — intervention group
Group type: COMPARATOR
Intervention: Standard counseling alone
Number of subjects: 219
Study 30703258 — intervention group
Group type: EXPERIMENTAL
Intervention: BMS-986231 0.1, 0.33, 1, 3, 5, 10, and 15 μg/kg/min infused over 24 hours
Number of subjects: 80
Study 30703258 — intervention group
Group type: EXPERIMENTAL
Intervention: BMS-986231 10 μg/kg/min infused over 48 hours
Number of subjects: 80
Study 30703258 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 29509839 — intervention group
Group type: EXPERIMENTAL
Intervention: Same-day home-based ART initiation (n=138)
Number of subjects: 278
Study 29509839 — intervention group
Group type: COMPARATOR
Intervention: Usual care (n=140)
Number of subjects: 278
Study 26895920 — intervention group
Group type: EXPERIMENTAL
Intervention: Protective lung ventilation (low tidal volume of 6 ml/kg with PEEP of 5 cmH2O)
Number of subjects: 62
Study 26895920 — intervention group
Group type: COMPARATOR
Intervention: Conventional ventilation with alveolar recruitment maneuver (tidal volume of 10 ml/kg with inspiratory pressure of 40 cmH2O for 30s)
Number of subjects: 62
Study 24313385 — intervention group
Group type: EXPERIMENTAL
Intervention: UV-VL sunscreen with iron oxide as a VL-absorbing pigment, SPF ≥ 50, used over 8 weeks
Number of subjects: 68
Study 24313385 — intervention group
Group type: COMPARATOR
Intervention: UV-only broad-spectrum sunscreen, SPF ≥ 50, used over 8 weeks
Number of subjects: 68
Study 22562082 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous SCT
Number of subjects: 105
Study 22562082 — intervention group
Group type: COMPARATOR
Intervention: Allogeneic SCT
Number of subjects: 105
Study 20051131 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental health nurse supplementary prescribing
Number of subjects: 45
Study 20051131 — intervention group
Group type: COMPARATOR
Intervention: Independent medical prescribing
Number of subjects: 45
Study 17355901 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic Disease Self-Management Program (CDSMP)
Number of subjects: 139
Study 17355901 — intervention group
Group type: COMPARATOR
Intervention: Care-as-usual
Number of subjects: 139
Study 15957991 — intervention group
Group type: EXPERIMENTAL
Intervention: Temporising treatment of severe early onset pre-eclampsia
Number of subjects: 193
Study 15957991 — intervention group
Group type: COMPARATOR
Intervention: Control group I (born at the duration of pregnancy of the pre-eclamptic mother on admission)
Number of subjects: 193
Study 15957991 — intervention group
Group type: COMPARATOR
Intervention: Control group II (born at the same gestational age as the infant of the pre-eclamptic mother)
Number of subjects: 193
Study 12919267 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational package on baby walker use
Number of subjects: 64
Study 12919267 — intervention group
Group type: EXPERIMENTAL
Intervention: Advice on walkers
Number of subjects: 64
Study 12919267 — intervention group
Group type: EXPERIMENTAL
Intervention: Current practice regarding walker discussions
Number of subjects: 64
Study 12919267 — intervention group
Group type: EXPERIMENTAL
Intervention: Knowledge of walker-related injuries
Number of subjects: 64
Study 12919267 — intervention group
Group type: EXPERIMENTAL
Intervention: Resources for discussing walkers
Number of subjects: 64
Study 10396013 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Therapy (CBT)
Number of subjects: 65
Study 10396013 — intervention group
Group type: COMPARATOR
Intervention: Care as usual
Number of subjects: 65
Study 8984227 — intervention group
Group type: EXPERIMENTAL
Intervention: doxazosin
Number of subjects: 9
Study 8984227 — intervention group
Group type: EXPERIMENTAL
Intervention: moduretic
Number of subjects: 9
Study 8984227 — intervention group
Group type: EXPERIMENTAL
Intervention: amlodipine
Number of subjects: 9
Study 1767898 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous lumbar epidural infusion of morphine
Number of subjects: 64
Study 1767898 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous lumbar epidural infusion of fentanyl
Number of subjects: 64
Study 1767898 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular morphine
Number of subjects: 64
Study 1767898 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 64
Study 1767898 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic administration of loratadine
Number of subjects: 64
Study 7332913 — intervention group
Group type: EXPERIMENTAL
Intervention: Elixophyllin SR capsules
Number of subjects: 20
Study 7332913 — intervention group
Group type: COMPARATOR
Intervention: Theo-Dur tablets
Number of subjects: 20
Study 30264972 — intervention group
Group type: EXPERIMENTAL
Intervention: FIFA 11+ injury prevention program (10 weeks, 2 sessions/week)
Number of subjects: 71
Study 30264972 — intervention group
Group type: COMPARATOR
Intervention: Regular futsal warm-ups (control group)
Number of subjects: 71
Study 29742718 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA)
Number of subjects: 51
Study 29742718 — intervention group
Group type: COMPARATOR
Intervention: Transcutaneous electric nerve stimulation (TENS)
Number of subjects: 51
Study 25059332 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral moisturising gel containing egg yolk antibodies against Candida albicans (anti‐CA IgY)
Number of subjects: 0
Study 25059332 — intervention group
Group type: COMPARATOR
Intervention: Placebo oral moisturising gel without anti‐CA IgY
Number of subjects: 0
Study 23868719 — intervention group
Group type: EXPERIMENTAL
Intervention: Portuguese speakers
Number of subjects: 0
Study 23868719 — intervention group
Group type: COMPARATOR
Intervention: English speakers
Number of subjects: 0
Study 22440906 — intervention group
Group type: EXPERIMENTAL
Intervention: Biocompatible solution
Number of subjects: 185
Study 22440906 — intervention group
Group type: COMPARATOR
Intervention: Conventional solution
Number of subjects: 185
Study 19514864 — intervention group
Group type: EXPERIMENTAL
Intervention: losartan 25mg/chlorthalidone 6.25 mg
Number of subjects: 131
Study 19514864 — intervention group
Group type: COMPARATOR
Intervention: losartan 25 mg/hydrochlorothiazide 12.5 mg
Number of subjects: 131
Study 19514864 — intervention group
Group type: EXPERIMENTAL
Intervention: losartan 25mg/chlorthalidone 12.5 mg
Number of subjects: 131
Study 19514864 — intervention group
Group type: COMPARATOR
Intervention: losartan 50 mg/hydrochlorothiazide 12.5 mg
Number of subjects: 131
Study 17688161 — intervention group
Group type: EXPERIMENTAL
Intervention: Bimanual coordination program (sport stacking)
Number of subjects: 41
Study 17688161 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 41
Study 16008927 — intervention group
Group type: EXPERIMENTAL
Intervention: Video-thoracoscopy
Number of subjects: 47
Study 16008927 — intervention group
Group type: COMPARATOR
Intervention: Routine open thoracotomy
Number of subjects: 47
Study 11985943 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic supplement (50 ml curd containing Lactobacillus acidophilus)
Number of subjects: 100
Study 11985943 — intervention group
Group type: COMPARATOR
Intervention: Isocaloric supplement (control group)
Number of subjects: 100
Study 9891891 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05% levocabastine (BID)
Number of subjects: 93
Study 9891891 — intervention group
Group type: COMPARATOR
Intervention: 0.1% lodoxamide (QID)
Number of subjects: 93
Study 7636683 — intervention group
Group type: EXPERIMENTAL
Intervention: Packaged rice-based oral rehydration solution (R-ORS)
Number of subjects: 300
Study 7636683 — intervention group
Group type: COMPARATOR
Intervention: Standard glucose-electrolyte oral rehydration solution (G-ORS)
Number of subjects: 300
Study 2651490 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam
Number of subjects: 55
Study 2651490 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 55
Study 2651490 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study 367712 — intervention group
Group type: EXPERIMENTAL
Intervention: Acebutolol (400 to 800 mg daily)
Number of subjects: 30
Study 367712 — intervention group
Group type: COMPARATOR
Intervention: Methyldopa (500 to 1000 mg daily)
Number of subjects: 30
Study 367712 — intervention group
Group type: EXPERIMENTAL
Intervention: Acebutolol
Number of subjects: 30
Study 31517745 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin administered 12 hours before the operation
Number of subjects: 121
Study 31517745 — intervention group
Group type: COMPARATOR
Intervention: Low-molecular-weight heparin administered 1 hour before the operation
Number of subjects: 121
Study 28008603 — intervention group
Group type: EXPERIMENTAL
Intervention: Chair Yoga
Number of subjects: 131
Study 28008603 — intervention group
Group type: COMPARATOR
Intervention: Health Education Program (HEP)
Number of subjects: 131
Study 26384014 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac Rehabilitation (CR)
Number of subjects: 2198
Study 26384014 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac Rehabilitation (CR) in depressed patients
Number of subjects: 2198
Study 26384014 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac Rehabilitation (CR) in non-depressed patients
Number of subjects: 2198
Study 23421844 — intervention group
Group type: EXPERIMENTAL
Intervention: PREP delivered by clergy
Number of subjects: 193
Study 23421844 — intervention group
Group type: EXPERIMENTAL
Intervention: PREP delivered by professionals
Number of subjects: 193
Study 23421844 — intervention group
Group type: COMPARATOR
Intervention: Naturally occurring services
Number of subjects: 193
Study 23421844 — intervention group
Group type: EXPERIMENTAL
Intervention: PREP
Number of subjects: 193
Study 23421844 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-of-origin background
Number of subjects: 193
Study 21157403 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg sotrastaurin twice daily with standard-exposure tacrolimus (treatment B)
Number of subjects: 216
Study 21157403 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg sotrastaurin twice daily with reduced-exposure tacrolimus (treatment C)
Number of subjects: 216
Study 21157403 — intervention group
Group type: COMPARATOR
Intervention: mycophenolic acid (MPA) with standard-exposure tacrolimus (treatment A)
Number of subjects: 216
Study 19524401 — intervention group
Group type: EXPERIMENTAL
Intervention: Dobutamine stress echocardiography (DSE) at 20 microg/kg/min and peak stress
Number of subjects: 219
Study 19524401 — intervention group
Group type: EXPERIMENTAL
Intervention: Dobutamine stress echocardiography (DSE) at peak stress
Number of subjects: 219
Study 19524401 — intervention group
Group type: EXPERIMENTAL
Intervention: Dobutamine stress echocardiography (DSE) from 20 microg/kg/min to peak stress
Number of subjects: 219
Study 19524401 — intervention group
Group type: EXPERIMENTAL
Intervention: Changes in e' velocity and E/e' during DSE
Number of subjects: 219
Study 17556790 — intervention group
Group type: EXPERIMENTAL
Intervention: Isotretinoin (Acutaneï) therapy
Number of subjects: 200
Study 17556790 — intervention group
Group type: COMPARATOR
Intervention: Oral or topical acne therapy (control group)
Number of subjects: 200
Study 15453970 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjects with brain damage (emotion task)
Number of subjects: 0
Study 15453970 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjects with brain damage (personality task)
Number of subjects: 0
Study 15453970 — intervention group
Group type: COMPARATOR
Intervention: Neurologically normal subjects
Number of subjects: 0
Study 15453970 — intervention group
Group type: EXPERIMENTAL
Intervention: Lesion overlap analysis
Number of subjects: 0
Study 11478339 — intervention group
Group type: EXPERIMENTAL
Intervention: AIDA simulator (active intervention)
Number of subjects: 0
Study 11478339 — intervention group
Group type: COMPARATOR
Intervention: Conventional educational methods (control group)
Number of subjects: 0
Study 10223254 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral brain lesions from pre- or perinatal strokes
Number of subjects: 40
Study 10223254 — intervention group
Group type: COMPARATOR
Intervention: Matched controls
Number of subjects: 40
Study 10223254 — intervention group
Group type: EXPERIMENTAL
Intervention: Left-hemisphere damage
Number of subjects: 40
Study 10223254 — intervention group
Group type: EXPERIMENTAL
Intervention: Right-hemisphere damage
Number of subjects: 40
Study 10223254 — intervention group
Group type: EXPERIMENTAL
Intervention: Parietal lobe involvement (regardless of lesion side)
Number of subjects: 40
Study 10223254 — intervention group
Group type: EXPERIMENTAL
Intervention: Lesion severity
Number of subjects: 40